-
LEVERAGING AI-DRIVEN NATURAL LANGUAGE PROCESSING TO ENHANCE SYMPTOM CAPTURE IN PRIMARY BILIARY CHOLANGITIS (PBC) AND PRIMARY SCLEROSING CHOLANGITIS (PSC)
Mar 18, 2026, 21:38 PM -
COMPARING HEALTH OUTCOMES BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) STATUS AND RISK LEVEL: FINDINGS FROM THE US NATIONAL HEALTH AND WELLNESS SURVEY
Mar 18, 2026, 21:38 PM -
PATIENT-CENTRIC PATHWAYS: SURVEYING TREATMENT ACCESS AND SUPPORT FOR RARE DISEASES, INCLUDING RARE CANCERS, IN EUROPE
Mar 18, 2026, 21:38 PM -
MAPPING PATIENT-REPORTED OUTCOMES EVIDENCE REQUIREMENTS ACROSS GLOBAL MARKETS
Mar 18, 2026, 21:38 PM -
REAL-WORLD COMPARATIVE EFFECTIVENESS AND SAFETY OF TERLIPRESSIN VERSUS CONVENTIONAL THERAPY IN HOSPITALIZED ADULTS WITH HEPATORENAL SYNDROME
Mar 18, 2026, 21:38 PM -
MIND THE GAP:EVALUATION OF ARTIFICIAL INTELLIGENCE (AI) ASSISTED EVIDENCE GAP ANALYSIS APPROACHES FOR PCSK-9 INHIBITORS
Mar 18, 2026, 21:38 PM -
JAV-RARAS: MAPPING THE MULTIDIMENSIONAL BURDEN OF MUCOPOLYSACCHARIDOSIS TYPE IVA (MPS IVA), TYPE VI (MPS VI), AND SPINAL MUSCULAR ATROPHY (SMA) ON PATIENT QUALITY OF LIFE IN BRAZIL
Mar 18, 2026, 21:38 PM -
CLINICAL DEVELOPMENT LANDSCAPE AND CHARACTERISTICS OF RARE DISEASES IN THE U.S.
Mar 18, 2026, 21:38 PM -
ELECTRONIC HEALTH RECORDS VERSUS ADMINISTRATIVE CLAIMS TO SUPPORT PHARMACOVIGILANCE REVIEW OF SAFETY EVENTS: A FIT-FOR-PURPOSE EVALUATION
Mar 18, 2026, 21:38 PM -
EVALUATION AND VALIDATION OF A NOVEL POISON SEVERITY AND MORTALITY SCALE: A PILOT STUDY
Mar 18, 2026, 21:38 PM -
FAERS DATABASE ANALYSIS REVEALS ANENCEPHALY ASSOCIATED WITH ANTIRETROVIRAL DRUG EXPOSURE
Mar 18, 2026, 21:38 PM -
ALIGNMENT OF PATIENT-REPORTED OUTCOME IMPROVEMENTS WITH ICER COST-EFFECTIVENESS AND VALUE-BASED PRICE RECOMMENDATIONS IN RHEUMATOID ARTHRITIS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF THE HIV TEST AND TREAT STRATEGY IN DOWNSTAGING CERVICAL CANCER AMONG HIV-POSITIVE WOMEN IN TANZANIA: EVIDENCE AND IMPLICATIONS FOR LMICS
Mar 18, 2026, 21:38 PM -
REAL-WORLD CTDNA TEST UTILIZATION AND ASSOCIATED COSTS IN US PATIENTS WITH BLADDER CANCER WHO UNDERWENT RADICAL CYSTECTOMY
Mar 18, 2026, 21:38 PM -
SPENDING ON GENE THERAPIES FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Mar 18, 2026, 21:38 PM -
AVOIDABLE HYPERTENSIVE ADMISSIONS: ACUTE COMPLICATIONS AND HOSPITAL UTILIZATION IN CHILE’S PUBLIC SECTOR
Mar 18, 2026, 21:38 PM -
CULTURAL ADAPTATION AND LINGUISTIC VALIDATION OF THE CANCER AWARENESS MEASURE FOR INDIVIDUALS WITH INTELLECTUAL DISABILITIES IN HUNGARY
Mar 18, 2026, 21:38 PM -
THE ECONOMIC IMPACT OF METABOLIC SYNDROME IN SCHIZOPHRENIA: A CLAIMS-BASED ANALYSIS IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
WHY CURRENT INTERTEMPORAL DISCOUNTING METHODS ARE WRONG, HOW THEY DISTORT HEALTH TECHNOLOGY ASSESSMENT, COST-EFFECTIVENESS ANALYSIS AND ESTIMATES OF THE VALUE OF A LIFE-YEAR AT FULL HEALTH, AND HOW TO FIX THE PROBLEM
Mar 18, 2026, 21:38 PM -
CLINICAL TRIAL EVIDENCE SUPPORTING FDA APPROVAL OF NOVEL AGENTS IN 2024
Mar 18, 2026, 21:38 PM
